Loading…

Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?

Mass spectrometry (MS) methods are being widely used these days in medical laboratories for quantifying many small molecular analytes as well as for microbiological purposes. Little use has been made so far, however, of MS for analyzing peptides and proteins in clinical laboratory (an approach known...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2017-04, Vol.467, p.51-58
Main Authors: Lehmann, Sylvain, Brede, Cato, Lescuyer, Pierre, Cocho, José A., Vialaret, Jérôme, Bros, Pauline, Delatour, Vincent, Hirtz, Christophe
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c457t-e8950dc95bdf7380d816c18f2d4667c4d6fea44e9f156fbecc4910ce976887653
cites cdi_FETCH-LOGICAL-c457t-e8950dc95bdf7380d816c18f2d4667c4d6fea44e9f156fbecc4910ce976887653
container_end_page 58
container_issue
container_start_page 51
container_title Clinica chimica acta
container_volume 467
creator Lehmann, Sylvain
Brede, Cato
Lescuyer, Pierre
Cocho, José A.
Vialaret, Jérôme
Bros, Pauline
Delatour, Vincent
Hirtz, Christophe
description Mass spectrometry (MS) methods are being widely used these days in medical laboratories for quantifying many small molecular analytes as well as for microbiological purposes. Little use has been made so far, however, of MS for analyzing peptides and proteins in clinical laboratory (an approach known as clinical MS proteomics (cMSP)). The explanation for this situation may be that cMSP assays are more complex to implement than conventional assays, require large investments in terms of equipment and training, and have not yet been sufficiently validated for clinical applications. In addition, the protein analysis assays currently used in medical laboratories mostly meet both laboratory and clinical requirements in terms of analytical performances, ease of use, and turn-around-time. With the spread of MS methods in laboratories, increasing interest seems to be focusing on the development of MS for quantifying new analytes. MALDI-TOF MS methods have already been replacing classical methods of bacterial classification in clinical laboratories, for example, and this can be said to be an important step in this direction. In this paper, the literature available on the topic of clinical MS proteomics is reviewed and the pre-analytical, analytical, and post-analytical challenges which will have to be met in connection with this approach are discussed. •Mass Spectrometry is becoming more common at medical laboratory•Clinical Mass Spectrometry Proteomics (cMSP) is a new clinical chemistry field•cMSP has important pre-analytical, analytical, and post-analytical challenges but also important potential
doi_str_mv 10.1016/j.cca.2016.06.001
format article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01842326v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009898116302467</els_id><sourcerecordid>1859710064</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-e8950dc95bdf7380d816c18f2d4667c4d6fea44e9f156fbecc4910ce976887653</originalsourceid><addsrcrecordid>eNp9kV2LEzEUhoMobl39Ad5ILncvpiYzmUyiF8tS1BUqCipehvTkhKbMNDXJLPTfm9p1L4UD-eDJA3lfQl5ztuSMy7e7JYBdtnW7ZHUYf0IWXA1d0wndPiULxphulFb8grzIeVePgkn-nFy0Qyv7vu0WxKzGsA9gRzrZnGk-IJQUJyzpSA8pFoxTgEyv4Mv3b9fUx0QndH_50W5isiWm4zv6a2sLdREzLVukfi5zQrqNo7t5SZ55O2Z89bBekp8fP_xY3TXrr58-r27XDYh-KA0q3TMHut84P3SKOcUlcOVbJ6QcQDjp0QqB2vNe-g0CCM0ZoB6kUoPsu0tyffZu7WgOKUw2HU20wdzdrs3pjnEl2q6V97yyV2e2fvD3jLmYKWTAcbR7jHM2XPV64IxJUVF-RiHFnBP6Rzdn5tSB2ZnagTl1YFgddtK_edDPmxrW44t_oVfg_RnAGsh9wGQyBNxDDTbV-I2L4T_6P8aBlfA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859710064</pqid></control><display><type>article</type><title>Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?</title><source>ScienceDirect Freedom Collection</source><creator>Lehmann, Sylvain ; Brede, Cato ; Lescuyer, Pierre ; Cocho, José A. ; Vialaret, Jérôme ; Bros, Pauline ; Delatour, Vincent ; Hirtz, Christophe</creator><creatorcontrib>Lehmann, Sylvain ; Brede, Cato ; Lescuyer, Pierre ; Cocho, José A. ; Vialaret, Jérôme ; Bros, Pauline ; Delatour, Vincent ; Hirtz, Christophe ; on behalf of the IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP) ; IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)</creatorcontrib><description>Mass spectrometry (MS) methods are being widely used these days in medical laboratories for quantifying many small molecular analytes as well as for microbiological purposes. Little use has been made so far, however, of MS for analyzing peptides and proteins in clinical laboratory (an approach known as clinical MS proteomics (cMSP)). The explanation for this situation may be that cMSP assays are more complex to implement than conventional assays, require large investments in terms of equipment and training, and have not yet been sufficiently validated for clinical applications. In addition, the protein analysis assays currently used in medical laboratories mostly meet both laboratory and clinical requirements in terms of analytical performances, ease of use, and turn-around-time. With the spread of MS methods in laboratories, increasing interest seems to be focusing on the development of MS for quantifying new analytes. MALDI-TOF MS methods have already been replacing classical methods of bacterial classification in clinical laboratories, for example, and this can be said to be an important step in this direction. In this paper, the literature available on the topic of clinical MS proteomics is reviewed and the pre-analytical, analytical, and post-analytical challenges which will have to be met in connection with this approach are discussed. •Mass Spectrometry is becoming more common at medical laboratory•Clinical Mass Spectrometry Proteomics (cMSP) is a new clinical chemistry field•cMSP has important pre-analytical, analytical, and post-analytical challenges but also important potential</description><identifier>ISSN: 0009-8981</identifier><identifier>EISSN: 1873-3492</identifier><identifier>DOI: 10.1016/j.cca.2016.06.001</identifier><identifier>PMID: 27265523</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Clinical chemistry ; Clinical Laboratory Techniques - methods ; Clinical Laboratory Techniques - standards ; Humans ; Laboratory medicine ; Life Sciences ; Mass spectrometry ; Mass Spectrometry - methods ; Mass Spectrometry - standards ; Proteomics ; Proteomics - methods ; Proteomics - standards ; Reproducibility of Results</subject><ispartof>Clinica chimica acta, 2017-04, Vol.467, p.51-58</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-e8950dc95bdf7380d816c18f2d4667c4d6fea44e9f156fbecc4910ce976887653</citedby><cites>FETCH-LOGICAL-c457t-e8950dc95bdf7380d816c18f2d4667c4d6fea44e9f156fbecc4910ce976887653</cites><orcidid>0000-0002-3730-2366 ; 0000-0001-6117-562X ; 0000-0002-7313-0629</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27265523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-01842326$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Lehmann, Sylvain</creatorcontrib><creatorcontrib>Brede, Cato</creatorcontrib><creatorcontrib>Lescuyer, Pierre</creatorcontrib><creatorcontrib>Cocho, José A.</creatorcontrib><creatorcontrib>Vialaret, Jérôme</creatorcontrib><creatorcontrib>Bros, Pauline</creatorcontrib><creatorcontrib>Delatour, Vincent</creatorcontrib><creatorcontrib>Hirtz, Christophe</creatorcontrib><creatorcontrib>on behalf of the IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)</creatorcontrib><creatorcontrib>IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)</creatorcontrib><title>Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?</title><title>Clinica chimica acta</title><addtitle>Clin Chim Acta</addtitle><description>Mass spectrometry (MS) methods are being widely used these days in medical laboratories for quantifying many small molecular analytes as well as for microbiological purposes. Little use has been made so far, however, of MS for analyzing peptides and proteins in clinical laboratory (an approach known as clinical MS proteomics (cMSP)). The explanation for this situation may be that cMSP assays are more complex to implement than conventional assays, require large investments in terms of equipment and training, and have not yet been sufficiently validated for clinical applications. In addition, the protein analysis assays currently used in medical laboratories mostly meet both laboratory and clinical requirements in terms of analytical performances, ease of use, and turn-around-time. With the spread of MS methods in laboratories, increasing interest seems to be focusing on the development of MS for quantifying new analytes. MALDI-TOF MS methods have already been replacing classical methods of bacterial classification in clinical laboratories, for example, and this can be said to be an important step in this direction. In this paper, the literature available on the topic of clinical MS proteomics is reviewed and the pre-analytical, analytical, and post-analytical challenges which will have to be met in connection with this approach are discussed. •Mass Spectrometry is becoming more common at medical laboratory•Clinical Mass Spectrometry Proteomics (cMSP) is a new clinical chemistry field•cMSP has important pre-analytical, analytical, and post-analytical challenges but also important potential</description><subject>Clinical chemistry</subject><subject>Clinical Laboratory Techniques - methods</subject><subject>Clinical Laboratory Techniques - standards</subject><subject>Humans</subject><subject>Laboratory medicine</subject><subject>Life Sciences</subject><subject>Mass spectrometry</subject><subject>Mass Spectrometry - methods</subject><subject>Mass Spectrometry - standards</subject><subject>Proteomics</subject><subject>Proteomics - methods</subject><subject>Proteomics - standards</subject><subject>Reproducibility of Results</subject><issn>0009-8981</issn><issn>1873-3492</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kV2LEzEUhoMobl39Ad5ILncvpiYzmUyiF8tS1BUqCipehvTkhKbMNDXJLPTfm9p1L4UD-eDJA3lfQl5ztuSMy7e7JYBdtnW7ZHUYf0IWXA1d0wndPiULxphulFb8grzIeVePgkn-nFy0Qyv7vu0WxKzGsA9gRzrZnGk-IJQUJyzpSA8pFoxTgEyv4Mv3b9fUx0QndH_50W5isiWm4zv6a2sLdREzLVukfi5zQrqNo7t5SZ55O2Z89bBekp8fP_xY3TXrr58-r27XDYh-KA0q3TMHut84P3SKOcUlcOVbJ6QcQDjp0QqB2vNe-g0CCM0ZoB6kUoPsu0tyffZu7WgOKUw2HU20wdzdrs3pjnEl2q6V97yyV2e2fvD3jLmYKWTAcbR7jHM2XPV64IxJUVF-RiHFnBP6Rzdn5tSB2ZnagTl1YFgddtK_edDPmxrW44t_oVfg_RnAGsh9wGQyBNxDDTbV-I2L4T_6P8aBlfA</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Lehmann, Sylvain</creator><creator>Brede, Cato</creator><creator>Lescuyer, Pierre</creator><creator>Cocho, José A.</creator><creator>Vialaret, Jérôme</creator><creator>Bros, Pauline</creator><creator>Delatour, Vincent</creator><creator>Hirtz, Christophe</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-3730-2366</orcidid><orcidid>https://orcid.org/0000-0001-6117-562X</orcidid><orcidid>https://orcid.org/0000-0002-7313-0629</orcidid></search><sort><creationdate>201704</creationdate><title>Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?</title><author>Lehmann, Sylvain ; Brede, Cato ; Lescuyer, Pierre ; Cocho, José A. ; Vialaret, Jérôme ; Bros, Pauline ; Delatour, Vincent ; Hirtz, Christophe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-e8950dc95bdf7380d816c18f2d4667c4d6fea44e9f156fbecc4910ce976887653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Clinical chemistry</topic><topic>Clinical Laboratory Techniques - methods</topic><topic>Clinical Laboratory Techniques - standards</topic><topic>Humans</topic><topic>Laboratory medicine</topic><topic>Life Sciences</topic><topic>Mass spectrometry</topic><topic>Mass Spectrometry - methods</topic><topic>Mass Spectrometry - standards</topic><topic>Proteomics</topic><topic>Proteomics - methods</topic><topic>Proteomics - standards</topic><topic>Reproducibility of Results</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lehmann, Sylvain</creatorcontrib><creatorcontrib>Brede, Cato</creatorcontrib><creatorcontrib>Lescuyer, Pierre</creatorcontrib><creatorcontrib>Cocho, José A.</creatorcontrib><creatorcontrib>Vialaret, Jérôme</creatorcontrib><creatorcontrib>Bros, Pauline</creatorcontrib><creatorcontrib>Delatour, Vincent</creatorcontrib><creatorcontrib>Hirtz, Christophe</creatorcontrib><creatorcontrib>on behalf of the IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)</creatorcontrib><creatorcontrib>IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinica chimica acta</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lehmann, Sylvain</au><au>Brede, Cato</au><au>Lescuyer, Pierre</au><au>Cocho, José A.</au><au>Vialaret, Jérôme</au><au>Bros, Pauline</au><au>Delatour, Vincent</au><au>Hirtz, Christophe</au><aucorp>on behalf of the IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)</aucorp><aucorp>IFCC Working Group on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?</atitle><jtitle>Clinica chimica acta</jtitle><addtitle>Clin Chim Acta</addtitle><date>2017-04</date><risdate>2017</risdate><volume>467</volume><spage>51</spage><epage>58</epage><pages>51-58</pages><issn>0009-8981</issn><eissn>1873-3492</eissn><abstract>Mass spectrometry (MS) methods are being widely used these days in medical laboratories for quantifying many small molecular analytes as well as for microbiological purposes. Little use has been made so far, however, of MS for analyzing peptides and proteins in clinical laboratory (an approach known as clinical MS proteomics (cMSP)). The explanation for this situation may be that cMSP assays are more complex to implement than conventional assays, require large investments in terms of equipment and training, and have not yet been sufficiently validated for clinical applications. In addition, the protein analysis assays currently used in medical laboratories mostly meet both laboratory and clinical requirements in terms of analytical performances, ease of use, and turn-around-time. With the spread of MS methods in laboratories, increasing interest seems to be focusing on the development of MS for quantifying new analytes. MALDI-TOF MS methods have already been replacing classical methods of bacterial classification in clinical laboratories, for example, and this can be said to be an important step in this direction. In this paper, the literature available on the topic of clinical MS proteomics is reviewed and the pre-analytical, analytical, and post-analytical challenges which will have to be met in connection with this approach are discussed. •Mass Spectrometry is becoming more common at medical laboratory•Clinical Mass Spectrometry Proteomics (cMSP) is a new clinical chemistry field•cMSP has important pre-analytical, analytical, and post-analytical challenges but also important potential</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27265523</pmid><doi>10.1016/j.cca.2016.06.001</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3730-2366</orcidid><orcidid>https://orcid.org/0000-0001-6117-562X</orcidid><orcidid>https://orcid.org/0000-0002-7313-0629</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0009-8981
ispartof Clinica chimica acta, 2017-04, Vol.467, p.51-58
issn 0009-8981
1873-3492
language eng
recordid cdi_hal_primary_oai_HAL_hal_01842326v1
source ScienceDirect Freedom Collection
subjects Clinical chemistry
Clinical Laboratory Techniques - methods
Clinical Laboratory Techniques - standards
Humans
Laboratory medicine
Life Sciences
Mass spectrometry
Mass Spectrometry - methods
Mass Spectrometry - standards
Proteomics
Proteomics - methods
Proteomics - standards
Reproducibility of Results
title Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A10%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20mass%20spectrometry%20proteomics%20(cMSP)%20for%20medical%20laboratory:%20What%20does%20the%20future%20hold?&rft.jtitle=Clinica%20chimica%20acta&rft.au=Lehmann,%20Sylvain&rft.aucorp=on%20behalf%20of%20the%20IFCC%20Working%20Group%20on%20Clinical%20Quantitative%20Mass%20Spectrometry%20Proteomics%20(WG-cMSP)&rft.date=2017-04&rft.volume=467&rft.spage=51&rft.epage=58&rft.pages=51-58&rft.issn=0009-8981&rft.eissn=1873-3492&rft_id=info:doi/10.1016/j.cca.2016.06.001&rft_dat=%3Cproquest_hal_p%3E1859710064%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c457t-e8950dc95bdf7380d816c18f2d4667c4d6fea44e9f156fbecc4910ce976887653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1859710064&rft_id=info:pmid/27265523&rfr_iscdi=true